En del af Watch Medier

MedWatchlørdag4. februar 2023

  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Søg
  • Log ind
  • Seneste
  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
12.06.2019kl. 15.53

Danish Biogen director after factory sale: "It's a peaceful goodbye"

Biogen Denmark's business will continue as usual although the company has said goodbye to 800 employees with the divestment of its manufacturing site outside Copenhagen, says Managing Director Janne Harder.
af KEVIN GRØNNEMANN

The Danish unit of US biotech giant Biogen will become remarkably smaller when the company sells its production facilities north of Copenhagen to Japanese Fujifilm Diosynth Biotechnologies in August.

The approximately 800 factory staff members will continue to work for Fujifilm, which leaves Biogen Denmark with only 25 employees to handle sales, marketing, launches side effect reporting, advising and service functions.

This work will continue despite the factory sale, says Janne Harder, Managing Director at Biogen Denmark.

"We were technically split into two units, and the factory was a whole different branch. So, the fact that we don't have a factory actually doesn't affect us," she says to MedWatch.

Harder stresses that all employees in the factory have been offered to keep their jobs under Fujifilm's ownership so to her an her colleagues, the sale has been undramatic.

"It's a peaceful goodbye. Nobody was fired and there were no cuts," she says.

Growing profit

In 2018, Biogen Denmark - excluding the factory - had a revenue of DKK 355 million (USD 53.81 million) and generated a profit of DKK 12.5 million (USD 1.89 million). It was equal to an increase by respectively 1.5 percent and 37.4 percent relative to the previous year.

According to Harder, the growth is especially due to biosimilar drugs. In October 2018, Biogen launched a biosimilar version of the world's best selling drug, Humira, in Denmark.

One of Biogen Denmark's most important future tasks will be to expand the use of the spinal muscular atrophy (SMA) treatment, Spinraza. Biogen obtained approval of the drug for a certain group of children in May 2018 after a long dispute with the Danish Medicines Council.

"At the moment, we are working to expand the approval for type 2 and 3 SMA children, who currently don't receive treatment, and of course we will also work to obtain approval of Spinraza for adults," says Harder, adding:

"It's a long process. We have to collect the data the Medicines Council demands and we have to consider prices - how can we match what the Danish state is willing to pay with the pricing in the rest of Europe."

Moreover, the 25 remaining employees in Biogen Denmark are to continue to handle important marketing, reporting and service tasks.

"That's what the people in the US keep an eye on and expect from us," says the managing director.

In 2018, Biogen had a global revenue of USD 13.5 billion.

English Edit: Ida Løjmand

Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.

 New owner of former Biogen plant with 800 employees: "It gives us a much better offer" 

 Biogen director on factory sale: Fujifilm comes with a different business model 

Relaterede artikler:

  • Foto: Fujifilm

    New owner of former Biogen plant with 800 employees: "It gives us a much better offer"

    For abonnenter

  • Foto: Biogen

    Biogen director on factory sale: Fujifilm comes with a different business model

    For abonnenter

Tilmeld dig vores nyhedsbrev

Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

!
Nyhedsbrevsvilkår

Forsiden lige nu

Carsten Hellmann, adm. direktør i ALK | Foto: Gregers Tycho/Ritzau/Ritzau Scanpix
Medicinal & Biotek

Kampen om USA fortsætter for ALK: "Dem, der vinder, er dem, der ikke giver op"

Der er stadig langt op til fordums ambitioner om det amerikanske marked for ALK. Allergikoncernen har smidt allergologerne i skraldespanden og fokuserer nu benhårdt på børnelægerne efter en indikationsudvidelse tidligere på året.

For abonnenter

Foto: Novo Nordisk / Pr
Medicinal & Biotek

Sydbank: Wegovy holder stadig tempoet højt

Peter Lyhne Uhrenholt indtrådte i april 2022 som adm. direktør for Estron. Investor Poul Thyregod sidder som bestyrelsesformand. | Foto: Estron / Pr
Høreapparater

Estron solgt til kapitalfond

Carsten Hellmann, adm. direktør i ALK, fik stort set lige meget i løn i 2022 som i 2021. | Foto: Gregers Tycho/Ritzau/Ritzau Scanpix
Medicinal & Biotek

Trods rekordresultat er ALK-topchefs lønpakke uændret i 2022

For abonnenter

Foto: Dado Ruvic
Medico & Rehab

Kinesiske myndigheder har godkendt produkt fra Coloplasts kæmpeopkøb

For abonnenter

Luja kan potentielt set være et produkt med den innovation, som har manglet i årevis på kateter-markedet. Traditionelle katetre har kun to huller, og hvis de blokeres under tømningen af blæren, skal kateteret flyttes, som kan give infektion. Det forsøger Luja at afhjælpe ved i stedet at have 80 små huller.
Medico & Rehab

Coloplast vil sætte ny behandlingsstandard med kateteret Luja men holder tæt om salgsforventninger

For abonnenter

Seneste nyt

  • Kampen om USA fortsætter for ALK: "Dem, der vinder, er dem, der ikke giver op" – 3. feb.
  • Sydbank: Wegovy holder stadig tempoet højt – 3. feb.
  • Estron solgt til kapitalfond – 3. feb.
  • Trods rekordresultat er ALK-topchefs lønpakke uændret i 2022 – 3. feb.
  • Kinesiske myndigheder har godkendt produkt fra Coloplasts kæmpeopkøb – 3. feb.
  • Kina accepterer behandling af allergitabletansøgning fra ALK – 3. feb.
  • ALK spår vækst på mellem 7-11 pct. i 2023 – lavere end i 2022 – 3. feb.
  • Medicinformand om anbefalinger til kortere sagsbehandling: Vil tage tid at implementere – 3. feb.
  • Coloplast vil sætte ny behandlingsstandard med kateteret Luja men holder tæt om salgsforventninger – 3. feb.
  • Medie: GN-formands exit kan genstarte opkøbsplaner – 3. feb.
  • Endnu en sten ryddet af vejen for at udskyde deadline for MDR-ordning – 3. feb.
  • Dupixent er nu en nidobbelt blockbuster – 3. feb.
  • Unilabs og Siemens Healthineers indgår milliardsamarbejde – 3. feb.
  • Sydbank: Coloplast viser bedre takter end ventet – 3. feb.
  • Coloplast lancerer kateter med ny teknologi – 3. feb.
Flere nyheder

Job

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Clinical Operational Associate

  • Erfaren Patentrådgiver

  • Senior Clinical Project Manager

  • Lead Data Architect

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Supply Chain Manager

  • Regulatory Affairs Professional

  • Medical Advisor (Metabolism)

  • Application Manager

  • Commercial Director

  • Specialist til udbud på lægemidler til danske sygehuse

Se flere jobs

Watch Job

  • Erfaren IT Supporter

  • Business Intelligence Specialist

  • Forvaltningsservicechef i Vestforbrænding

  • Salesforce-udvikler eller -arkitekt

  • Jurister søges til Corporate Legal i Danmarks Eksport & Investeringsfond

Se flere jobs

Job

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Clinical Operational Associate

  • Erfaren Patentrådgiver

  • Senior Clinical Project Manager

  • Lead Data Architect

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Supply Chain Manager

  • Regulatory Affairs Professional

  • Medical Advisor (Metabolism)

  • Application Manager

  • Commercial Director

  • Specialist til udbud på lægemidler til danske sygehuse

Se flere jobs

Kolofon

MedWatch
Søg

Sektioner

  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
  • Sitemap
  • RSS feeds

Redaktør

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tlf.: +45 3330 8387

Ansv. chefredaktør

Anders Heering

Udgiver

JP/Politikens Hus A/S

Annonceafdeling

annoncering@infowatch.dk

Tlf.: +45 7077 7441

Annoncering

Jobannoncering

job@infowatch.dk

Tlf.: +45 7077 7441

Job

Abonnement

Prøv MedWatch gratis eller få tilbud på et abonnement, der passer til lige netop dig eller din virksomhed.

medwatch@infowatch.dk

Tlf.: +45 7077 7441

Læs mere om abonnement her

Adresse

MedWatch

Rådhuspladsen 37

1785 København V

Tlf.: +45 3330 8370

Retningslinjer

  • Persondatapolitik

Copyright © MedWatch — Alt materiale på denne side er omfattet af gældende lov om ophavsret

Microsoft er i gang med at udfase Internet Explorer – det er vi derfor også.
Vi anbefaler en af følgende browsere for en bedre oplevelse. Klik på et af ikonerne for at downloade en ny browser.

Med venlig hilsen,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge